- Home
- ABL vs CGEM Comparison
ABL vs CGEM Comparison
Compare ABL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- CGEM
- Stock Information
- Founded
- ABL 2004
- CGEM 2016
- Country
- ABL United States
- CGEM United States
- Employees
- ABL N/A
- CGEM N/A
- Industry
- ABL Investment Managers
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- ABL Finance
- CGEM Health Care
- Exchange
- ABL Nasdaq
- CGEM Nasdaq
- Market Cap
- ABL 661.9M
- CGEM 482.7M
- IPO Year
- ABL N/A
- CGEM 2021
- Fundamental
- Price
- ABL $7.15
- CGEM $7.54
- Analyst Decision
- ABL Strong Buy
- CGEM Strong Buy
- Analyst Count
- ABL 3
- CGEM 7
- Target Price
- ABL $12.83
- CGEM $26.57
- AVG Volume (30 Days)
- ABL 661.4K
- CGEM 361.9K
- Earning Date
- ABL 08-07-2025
- CGEM 08-07-2025
- Dividend Yield
- ABL N/A
- CGEM N/A
- EPS Growth
- ABL N/A
- CGEM N/A
- EPS
- ABL N/A
- CGEM N/A
- Revenue
- ABL $161,724,466.00
- CGEM N/A
- Revenue This Year
- ABL $77.22
- CGEM N/A
- Revenue Next Year
- ABL $29.93
- CGEM N/A
- P/E Ratio
- ABL N/A
- CGEM N/A
- Revenue Growth
- ABL 69.56
- CGEM N/A
- 52 Week Low
- ABL $4.60
- CGEM $6.85
- 52 Week High
- ABL $10.95
- CGEM $19.89
- Technical
- Relative Strength Index (RSI)
- ABL 77.06
- CGEM 47.12
- Support Level
- ABL $6.23
- CGEM $7.50
- Resistance Level
- ABL $7.03
- CGEM $8.11
- Average True Range (ATR)
- ABL 0.27
- CGEM 0.38
- MACD
- ABL 0.08
- CGEM 0.01
- Stochastic Oscillator
- ABL 99.29
- CGEM 36.59
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.